Tag Archive for: complement-driven

Invizius receives MHRA approval to commence First-in-Human clinical study of H-Guard® Priming Solution

Invizius Limited (“Invizius”), a biotechnology company developing second generation therapies for a range of complement-driven autoimmune and inflammatory disorders, is pleased to announce that it has received approval from the UK Medicines and Healthcare products Regulatory Agency (MHRA) to commence its First-in-Human clinical study of lead product, H-Guard. The study will be conducted at the […]